Barclays PLC Mirum Pharmaceuticals, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Mirum Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 245,918 shares of MIRM stock, worth $10.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

245,918

Previous 245,918 -0.0%

Holding current value

$10.3 Million

Previous $9.59 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$33.68 - $44.74 $364,552 - $484,265	10,824 Added 4.6%	245,918 $9.59 Million
Q2 2024 Aug 14, 2024	SELL	$23.57 - $34.85 $937,426 - $1.39 Million	-39,772 Reduced 14.47%	235,094 $8.04 Million
Q1 2024 May 15, 2024	BUY	$24.92 - $30.02 $4.36 Million - $5.25 Million	174,944 Added 175.08%	274,866 $6.9 Million
Q4 2023 Feb 15, 2024	SELL	$27.14 - $34.93 $5.41 Million - $6.96 Million	-199,198 Reduced 66.59%	99,922 $2.95 Million
Q3 2023 Nov 07, 2023	BUY	$24.63 - $32.85 $294,821 - $393,214	11,970 Added 4.17%	299,120 $9.45 Million
Q2 2023 Aug 03, 2023	SELL	$23.51 - $30.09 $289,478 - $370,498	-12,313 Reduced 4.11%	287,150 $7.43 Million
Q1 2023 May 04, 2023	SELL	$19.19 - $24.1 $1.5 Million - $1.88 Million	-78,109 Reduced 20.69%	299,463 $7.19 Million
Q4 2022 Feb 13, 2023	BUY	$17.59 - $23.83 $5.08 Million - $6.88 Million	288,695 Added 324.83%	377,572 $7.36 Million
Q3 2022 Nov 03, 2022	BUY	$19.98 - $29.44 $1.31 Million - $1.93 Million	65,621 Added 282.17%	88,877 $1.87 Million
Q2 2022 Aug 12, 2022	SELL	$18.42 - $27.5 $111,680 - $166,732	-6,063 Reduced 20.68%	23,256 $453,000
Q1 2022 May 16, 2022	BUY	$15.5 - $23.93 $454,444 - $701,603	29,319 New	29,319 $646,000

Others Institutions Holding MIRM

# of Institutions

190

Shares Held

54M

Call Options Held

177K

Put Options Held

167K

View Full List

About Mirum Pharmaceuticals, Inc.

Ticker MIRM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,751,700
Market Cap $1.53B
Description
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...

More about MIRM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account